| 44.96 0.33 (0.74%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 52.53 | 1-year : | 61.36 |
| Resists | First : | 44.97 | Second : | 52.53 |
| Pivot price | 43.41  |
|||
| Supports | First : | 41.22 |
Second : | 38.9 |
| MAs | MA(5) : | 44.71 |
MA(20) : | 42.76 |
| MA(100) : | 41.92 |
MA(250) : | 35.45 |
|
| MACD | MACD : | 0.9 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 99.3 |
D(3) : | 98.1 |
| RSI | RSI(14): 72.4 | |||
| 52-week | High : | 44.97 | Low : | 19.59 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CERE ] has closed below upper band by 19.3%. Bollinger Bands are 143.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 29 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 45.01 - 45.25 | 45.25 - 45.45 |
| Low: | 44.38 - 44.66 | 44.66 - 44.89 |
| Close: | 44.51 - 44.98 | 44.98 - 45.37 |
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Thu, 02 Oct 2025
Bain Set to Face Claims Over Cerevel Trades Before AbbVie Sale - Bloomberg Law News
Sun, 01 Jun 2025
CERE DEADLINE TUESDAY: ROSEN, NATIONAL TRIAL COUNSEL, - GlobeNewswire
Fri, 02 Aug 2024
AbbVie concludes acquisition of Cerevel Therapeutics for $8.7bn - Pharmaceutical Technology
Sun, 07 Jul 2024
Bain Capital-Backed Cerevel Therapeutics in $8bn Acquisition Talks with AbbVie - Private Equity Insights
Fri, 08 Dec 2023
Cerevel options trading surge before AbbVie deal news raises eyebrows - Reuters
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 182 (M) |
| Shares Float | 78 (M) |
| Held by Insiders | 15.3 (%) |
| Held by Institutions | 85.1 (%) |
| Shares Short | 5,980 (K) |
| Shares Short P.Month | 6,360 (K) |
| EPS | -2.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.09 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -29.8 % |
| Return on Equity (ttm) | -92.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -367 (M) |
| Levered Free Cash Flow | -212 (M) |
| PE Ratio | -16.47 |
| PEG Ratio | 0 |
| Price to Book value | 14.5 |
| Price to Sales | 0 |
| Price to Cash Flow | -22.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|